AFL 22-20

This AFL guidance to Medical Directors and other prescribing clinicians recommending:

· all residents with symptomatic COVID-19 be evaluated by a prescribing clinician to be considered for COVID-19 therapeutics

· evaluate all residents for any oral COVID-19 therapeutics drug-drug interaction risk, renal and hepatic impairment in advance of a COVID-19 diagnosis and indicate such information in charts to facilitate access to appropriate therapeutics when a COVID-19 diagnosis is made

· available guidance and resources for evaluating, prescribing, and obtaining COVID-19 therapeutics for residents, and encourages SNFs to provide information for healthcare personnel who test positive for COVID-19 to obtain treatment with appropriate therapeutics.

· all residents should be considered eligible to receive treatment for mild-to-moderate COVID-19 and should be evaluated by a prescribing clinician for consideration of COVID-19 therapeutics

It has a table with the products currently authorized for treating mild-moderately ill COVID-19 patients. These medications are no longer in short supply and should be prescribed whenever clinically appropriate. These products must be administered within 5-7 days of symptom onset, depending on the specific product.

It has additional information in the CDPH COVID-19 Test-to-Treat Playbook.

Communicate with the pharmacy to ensure oral antiviral therapeutics are readily available. Contact CDPHTherapeutics@cdph.ca.gov if the pharmacy or facility has difficulty obtaining supply.

Provide information for staff who test positive for COVID-19 to obtain treatment with appropriate therapeutics. Staff may seek care from their regular provider or at Test to Treat locations.

Clearpol Inc. does not make any guarantees regarding the accuracy of the opinions provided on our platform. Please use your own judgement.